Genentech Wins FDA Nod for First At-Home TED Treatment, Expanding…

Event summary

FDA approves Genentech’s Enspryng for thyroid eye disease (TED), the first at-home subcutaneous treatment option.
Enspryng demonstrated significant efficacy in reducing proptosis (52.9% vs. 23.4% placebo) and diplopia (60.7% vs. 25.8% placebo) in Phase III trials.
Approval marks Enspryng’s second indication, following its 2020 approval for neuromyelitis optica spectrum disorder (NMOSD).
Genentech seeks priority review for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a decision expected in January 2027.

The big picture

Genentech’s FDA approval for Enspryng in TED represents a strategic pivot into the rare disease space, complementing its existing neurology portfolio. The at-home subcutaneous administration addresses a critical unmet need, potentially expanding patient access and reducing treatment burdens. This approval also underscores the growing importance of IL-6R inhibitors in managing autoimmune and inflammatory conditions, positioning Genentech as a key player in this therapeutic class.

What we're watching

Therapeutic Expansion: Whether Genentech can leverage Enspryng’s success in TED to accelerate approvals in other autoimmune and inflammatory diseases, such as MOGAD and autoimmune encephalitis.
Market Penetration: The pace at which Genentech can capture market share in the TED space, given the limited treatment options currently available.
Regulatory Momentum: How the FDA’s priority review designation for Enspryng in MOGAD may influence the approval timeline and commercialization strategy for additional indications.